What Happened in the ACMD November 2020 Medical Cannabis Conclusion?

In November 2020, the Advisory Council on the Misuse of Drugs (ACMD) delivered a pivotal conclusion on medical cannabis that stirred discussion among patients, clinicians, and policymakers alike. The panel’s review built upon its previous work and the landmark 2018 rescheduling decision, but it also highlighted ongoing complexities around NHS funding, legal prescribing boundaries, and the cautious stance on unlicensed cannabis-based products.

If you’re a patient trying to understand what this means for you, or a prescriber navigating NHS rules and specialist-only prescribing, this post breaks down the key points from the November 2020 ACMD conclusion in straightforward language. We’ll also clarify common confusions around legal status vs funding, and point to useful resources like medicalcannabis.co.uk and releaf.co.uk for clinic listings and accessible explainer content.

Quick Recap: The 2018 Rescheduling and What It Changed

Before diving into the ACMD’s 2020 conclusions, it’s essential to understand the significance of the 2018 rescheduling of cannabis-based medicinal products in the UK.

  • Before 2018: Cannabis-derived medicines were classified as Schedule 1 drugs, meaning they were considered to have no medicinal value and were illegal to prescribe.
  • 2018 Rescheduling: The UK government reclassified cannabis-based products for medicinal use to Schedule 2, making them legally prescribable by specialist doctors under strict conditions.
  • What it meant: This move allowed certain cannabis-derived medicines to enter routine clinical use, but with the caveat that prescribing remains restricted to a specialist (rather than general practitioners), reflecting both the novelty and the need for clinical oversight.

In simple terms: 2018 made medical cannabis legal to prescribe—but only via specialists and with caution.

November 2020 ACMD Conclusion: What Did the Review Say?

The November 2020 ACMD cannabis review was a comprehensive assessment based on evidence over several years, reviewing clinical data, patient outcomes, and policy impacts since the 2018 rescheduling. Key conclusions included:

  1. Maintaining Specialist-Only Prescribing

    The ACMD reaffirmed that cannabis-based medicinal products should remain restricted to specialist prescribing. The rationale is that these drugs require expert assessment, balancing potential benefits with known and unknown risks.

  2. Supporting Clinical Research and Data Collection

    The council stressed the need for ongoing, high-quality clinical trials to build the evidence base. Despite promising anecdotal reports, robust evidence from randomised controlled trials remains limited but is growing.

  3. NHS Funding Caution

    The ACMD noted that NHS funding for medical cannabis remains cautious due to limited large-scale evidence and cost-effectiveness concerns. While prescribing is legal, access via NHS funding is rare and tightly controlled, often limited to trials or exceptional cases.

  4. Unlicensed Cannabis-Based Medicines

    Unlicensed cannabis-based products (often imported or pharmacy-made ‘specials’) pose regulatory challenges. The ACMD highlighted the NHS’s caution on funding and prescribing unlicensed treatments until more data ensure safety, efficacy, and quality.

In short: The ACMD supports legal, specialist-led prescribing but urges more evidence and prudent NHS funding.

Legal Prescribing vs NHS Funding: Why Access Remains Complex

A common point of confusion is mixing up legal prescribing with NHS funding. The ACMD’s work makes it clear that these are separate issues:

  • Legal Prescribing: Thanks to the 2018 rescheduling and confirmed by ACMD advice, qualified specialists can legally prescribe cannabis-based medicines where they see clinical need.
  • NHS Funding: Whether the NHS will pay for that prescription is a different question. NHS England and local commissioning groups often restrict funding until more robust evidence supports widespread use. This leads many patients to pay privately.

Put plainly: Just because a specialist doctor can write a prescription doesn’t mean the NHS will automatically fund it. This matters because many patients turn to private clinics where out-of-pocket costs can be high, but access is quicker than long NHS delays.

Specialist-Only Prescribing Rules: What Patients Should Know

The ACMD aligned with existing MHRA and NICE guidance that only specialists trained and experienced in relevant clinical areas should prescribe cannabis-based medicines. This means:

  • General practitioners currently do not prescribe cannabis-derived products as part of standard practice.
  • Specialists include neurologists, pain consultants, epileptologists, and other clinicians with subject-matter expertise.
  • Specialists will determine eligibility based on a patient’s clinical profile and evidence—plus, they weigh risks carefully.

If you’re considering medical cannabis, it’s worth knowing the exact specialist pathway needed and engaging clinics or patient groups to navigate referral steps. The directory at medicalcannabis.co.uk can help locate UK clinics that offer specialist assessment.

Understanding Unlicensed Cannabis-Based Medicines and NHS Caution

Another sticking point illuminated in the ACMD’s November 2020 conclusion is the role of unlicensed cannabis medicines, often called “specials.” These are products without full marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA).

Key takeaways include:

  • Unlicensed products do not have the same rigorous clinical data as licensed alternatives like Epidyolex or Sativex.
  • The NHS exercises caution prescribing and funding such treatments due to uncertainties around quality, consistency, and safety.
  • In some cases, patients receive unlicensed formulations when licensed options are unavailable or unsuitable—but this is exception rather than rule.

Patients should note: important to discuss fully with prescribers what products are licensed vs unlicensed and NHS funding implications. Further explanation on product types and prescribing nuances can be found on Releaf’s explainer pages.

Price and Cost Transparency

The November 2020 ACMD report did not include any specific pricing data or compare costs of cannabis-based products. This omission reflects the variability in private clinic pricing and NHS funding irregularities.

When prices are quoted in future official sources or verified clinic disclosures, it’s crucial to share them exactly and in context. If you’re curious about current price ranges in private assessments and prescriptions, medicalcannabis.co.uk is a user-friendly site that provides clinic info and patient cost insights.

Summary: What Patients and Clinicians Need to Take Away

Theme November 2020 ACMD Conclusion What It Means in Practice 2018 Rescheduling Confirmed legality of cannabis-based medicines prescribing under specialist control. Doctors can legally prescribe, but only specialists currently do. Evidence Review More high-quality studies needed; evidence improving but still limited. Prescribing carefully targeted; widespread NHS adoption cautious. NHS Funding Funding remains cautious; many patient requests not routinely covered. Many patients pay privately or join clinical trials. Unlicensed Products Use cautiously; limited funding and regulatory oversight. Discuss licensing status; NHS likely to fund only licensed products. Prescribing Rules Specialist-only prescribing to continue. Patients require referral to appropriate specialists.

Final Thoughts

The November 2020 ACMD conclusion reaffirmed much of the cautious but progressive regulatory approach to medical cannabis in the UK. Patients can be hopeful that the rules allowing legal prescribing remain, but should be realistic about current NHS funding limits and the specialist-only framework.

For now, if you’re investigating medical cannabis as a treatment option, use resources like medicalcannabis.co.uk to find clinics and learn about the pathways, and releaf.co.uk for clear, vergemagazine.co patient-friendly explanations. Remember, access is improving but requires expert guidance and often private funding.

As always, keep tracking official updates and new research, and if you hear vague claims like “the NHS now freely prescribes medical cannabis,” pause and check: the legal right to prescribe does not guarantee NHS-funded access.